Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3134]

ASH 2014: Sotarcept reduces transfusion burden in patients with myelodysplastic syndromes

ASH 2014: Sotarcept reduces transfusion burden in patients with myelodysplastic syndromes

ASH 2014: Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

ASH 2014: Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma

ASH 2014: New immunotherapy compound effective and safe in leukaemia patients with minimal residual disease

ASH 2014: New immunotherapy compound effective and safe in leukaemia patients with minimal residual disease

ASH 2014: T cell therapy leading to prolonged remission for children with aggressive leukaemia

ASH 2014: T cell therapy leading to prolonged remission for children with aggressive leukaemia

ASH 2014: Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma patients in phase III study

ASH 2014: Brentuximab vedotin prolongs post-transplant survival in hard-to-treat lymphoma patients in phase III...

ASH 2014: Stem cell transplantation safe for patients with HIV-associated lymphoma

ASH 2014: Stem cell transplantation safe for patients with HIV-associated lymphoma

ASH 2014: Carfilzomib represents potent, effective addition to standard multiple myeloma therapy in phase III study

ASH 2014: Carfilzomib represents potent, effective addition to standard multiple myeloma therapy in phase III study

ASH 2014: Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in phase I study

ASH 2014: Daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma in...

ASH 2014: Investigational antibody demonstrates efficacy and safety for aggressive multiple myeloma in phase I study

ASH 2014: Investigational antibody demonstrates efficacy and safety for aggressive multiple myeloma in phase I...

FDA approves blinatumomab for some forms of acute lymphoblastic leukaemia

FDA approves blinatumomab for some forms of acute lymphoblastic leukaemia

More from ecancer